ClinicaliQ Trial Snapshot
- The Role of METhanogens in the PROgression Of Parkinson’s Disease and Related Neurological Conditions — Recruiting • Non-phase study • Respiratory / COPD / Asthma • NCT07786116.
- What is being tested: The study investigates whether methane-producing gut bacteria (methanogens) contribute to Parkinson's disease progression and related neurological conditions, examining the mechanistic link between gastrointestinal dysfunction and neurodegeneration.
- Patient eligibility overview: The trial likely includes patients with Parkinson's disease and/or related neurological conditions, alongside control groups, stratified by gastrointestinal symptom severity (particularly constipation) to establish disease associations.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
Gut problems, such as constipation, can have an important impact on quality of life of people who have them, and have been associated with higher risk of developing neurological diseases such as Parkinson's or Alzheimer's disease. Recent studies suggest that gut problems may also have implications for the progression of these diseases, as constipation is a risk factor for faster Parkinson's and Alzheimer's progression. However, how constipation and brain diseases are linked is unknown. Previous research has suggested that gut changes may lead to inflammation, which could play a role…
Eligibility Snapshot
- : People with PD: * 55 years of age or above; * MDS criteria for Idiopathic PD; * H&Y
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.